Cypress Capital Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 764.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 193,447 shares of the biopharmaceutical company’s stock after buying an additional 171,068 shares during the quarter. Cypress Capital Management LLC’s holdings in Pfizer were worth $7,009,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also added to or reduced their stakes in PFE. North American Management Corp grew its holdings in Pfizer by 4.0% during the 1st quarter. North American Management Corp now owns 186,886 shares of the biopharmaceutical company’s stock valued at $6,771,000 after buying an additional 7,122 shares in the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Pfizer by 2.0% in the 1st quarter. Jones Financial Companies Lllp now owns 358,298 shares of the biopharmaceutical company’s stock valued at $12,981,000 after purchasing an additional 7,005 shares during the last quarter. Wellington Shields Capital Management LLC lifted its stake in shares of Pfizer by 7.6% in the 4th quarter. Wellington Shields Capital Management LLC now owns 104,766 shares of the biopharmaceutical company’s stock valued at $3,856,000 after purchasing an additional 7,405 shares during the last quarter. Kanawha Capital Management LLC lifted its stake in shares of Pfizer by 2.5% in the 1st quarter. Kanawha Capital Management LLC now owns 233,336 shares of the biopharmaceutical company’s stock valued at $8,454,000 after purchasing an additional 5,682 shares during the last quarter. Finally, Roosevelt Investment Group LLC lifted its stake in shares of Pfizer by 11.8% in the 1st quarter. Roosevelt Investment Group LLC now owns 91,124 shares of the biopharmaceutical company’s stock valued at $3,301,000 after purchasing an additional 9,625 shares during the last quarter. Hedge funds and other institutional investors own 64.22% of the company’s stock.
In other news, SVP Jennifer B. Damico sold 2,500 shares of Pfizer stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the transaction, the senior vice president now directly owns 13,748 shares in the company, valued at approximately $561,193.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.05% of the company’s stock.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.15. Pfizer had a return on equity of 24.55% and a net margin of 22.09%. The business had revenue of $14.58 billion for the quarter, compared to the consensus estimate of $13.41 billion. During the same period last year, the business posted $0.80 EPS. The business’s revenue was up 44.6% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 3.69 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, June 4th. Stockholders of record on Friday, May 7th were issued a $0.39 dividend. The ex-dividend date was Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.90%. Pfizer’s dividend payout ratio is presently 70.27%.
Several research firms have recently issued reports on PFE. Barclays raised their price objective on Pfizer from $37.00 to $40.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 5th. Royal Bank of Canada began coverage on Pfizer in a research note on Wednesday, April 7th. They set a “sector perform” rating and a $42.00 price target for the company. Mizuho reissued a “neutral” rating and set a $42.00 price target on shares of Pfizer in a research note on Wednesday, May 12th. TheStreet raised Pfizer from a “c+” rating to a “b-” rating in a research note on Monday, May 3rd. Finally, The Goldman Sachs Group set a $45.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Monday, May 24th. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $39.73.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Recommended Story: Technical Indicators – What is a Golden Cross?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.